<DOC>
	<DOCNO>NCT00962637</DOCNO>
	<brief_summary>Approximately 4 5 million men U.S. testosterone-deficient . Enclomiphene ( trans-clomiphene ) citrate ( Androxal ) evaluate determine Androxal increase serum testosterone level men secondary hypogonadism . Subjects randomly assign 1 4 treatment group . Appropriate amount medication dispense visit . Subjects take medication orally rub onto skin ( depend treatment assignment ) daily 6 month . Treatment visit occur approximately 4-week interval Months 1 , 2 , 3 6-week interval Months 4 , 5 , 6 .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Androxalâ„¢ Treatment Men With Secondary Hypogonadism</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Total serum testosterone concentration &lt; 300 ng/dL baseline Presence history prostate cancer Elevated PSA &gt; 3.5 ng/mL Additional inclusion exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Secondary Hypogonadism</keyword>
</DOC>